Sugemalimab plus chemotherapy for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new immunotherapy drug (sugemalimab) combined with chemotherapy as a first treatment for advanced non-small cell lung cancer. It aims to see if this combination works well in real-world patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have advanced (stage III or IV) non-small cell lung cancer that hasn't been treated with systemic therapy before.
- Your cancer does not have certain gene mutations (EGFR, ALK, ROS1, or RET).
- You are willing to use effective birth control if you are fertile.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—two chemotherapy medications (carboplatin and nab-paclitaxel) plus an immunotherapy drug (serplulimab)—as a first-line treatment for advanced squamous cell non-small cell lung cancer. The goal is to see if this combination works better than standard treatment and is safe for patients who haven't received prior systemic cancer treatment.
This trial tests a cancer-fighting antibody (sugemalimab) added to standard chemotherapy for stage III lung cancer that can’t be removed by surgery but may be treated with radiation. It aims to improve control of your cancer while checking safety and side effects.
This trial tests if adding the immunotherapy drug sugemalimab to standard chemotherapy before and after surgery can help people with stage II-IIIA non-small cell lung cancer. It aims to see if this combination reduces the chance of cancer coming back.
This trial tests sugemalimab as “extra treatment” after standard chemoradiation for limited-stage small cell lung cancer. It aims to lower the chance of the cancer coming back by helping the immune system stay active after initial therapy.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial combines surgery to remove the main lung tumor with chemo and an immunotherapy drug called sintilimab. It's for people with advanced non-small cell lung cancer that hasn't been treated before and doesn't have certain gene changes.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.